Pykus Therapeutics Expands Patent Portfolio for PYK-2101, a First-in-class Retinal Sealant Delivery Technology

-- PYK-2101 aims to provide rapid visual recovery, enhanced outcomes, and a dramatically improved post-operative experience for patients with retinal detachment, addressing critical unmet needs--

CAMBRIDGE, Mass., Feb. 26, 2025 /PRNewswire/ -- Pykus Therapeutics, Inc. ("Pykus" or the "Company"), a medical technology company dedicated to improving the lives of patients with blinding eye diseases, today announced it has secured a new patent from the United States Patent and Trademark Office for its next-generation biodegradable retinal sealant, PYK-2101. The issued patent, entitled "Hydrogel Formulations and Methods and Devices for Administration of the Same" (U.S. Patent No. 12,233,157), further strengthens Pykus' global intellectual property portfolio of more than a dozen issued and pending patents, covering novel biomaterials for the treatment of blinding vitreoretinal diseases. This patent is expected to provide robust protection of Pykus' lead clinical-stage asset, PYK-2101, into 2044.

"This patent issuance marks a major step forward in our effort to address critical gaps in current treatment paradigms for retina surgery. We are pleased to further strengthen our intellectual property portfolio as our clinical development programs continue to expand," stated Dr. Tommy Stryjewski, Chief Scientific Officer and co-founder of Pykus.

PYK-2101 is a first-in-class biodegradable retinal hydrogel sealant. The Company is pursuing an initial indication for the treatment of retinal detachment; PYK-2101 offers the opportunity to dramatically improve and accelerate visual recovery following retinal detachment surgery by sealing retinal breaks directly without having to obscure vision, while also eliminating the need for patients to have to position "face-down" after surgery. Compared to the current standard-of-care, which involves filling the eye with intraocular gases or silicone oil, PYK-2101 is expected to dramatically enhance the patient experience and improve surgical outcomes.

Currently, PYK-2101 is being investigated in a prospective, multicenter clinical trial in patients with retinal detachment in Australia. The Company anticipates providing a clinical update of its ongoing trial in the second quarter of this year.

For more insights into PYK-2101 and the groundbreaking impact it can have on patient outcomes in retina surgery, please refer to the product's explainer video available on the company's website.

About Pykus Therapeutics:
Pykus Therapeutics, Inc., based in Cambridge, MA, is a clinical-stage, medical technology company dedicated to advancing treatments for retinal and other ophthalmic diseases. Using technology originally developed by and licensed from the Mass. Eye and Ear Infirmary (now part of Mass General Brigham) at Harvard Medical School, the Company aims to deliver transformative solutions to improve surgical outcomes and enhance patient care. For more information, visit www.pykustherapeutics.com.

Contact:
Kelsey-Ann Leslie
Pykus Therapeutics
[email protected]

SOURCE Pykus Therapeutics